stockrowElicio Therapeutics, Inc.
ELTX Healthcare Biotechnology
- EPS
- +34.9%
- Free cash flow
- +8.77%
- Total debt
- +2.12%
Quarter to June 2026, against a year earlier
Follow ELTX
Alert me
Elicio Therapeutics, Inc. (ELTX) EV/Sales
As of 6 November 2026, Elicio Therapeutics, Inc. (ELTX) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from −9.9× (December 2021) to 128× (August 2021); the current reading is higher than 34% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | −0.2× | — |
| FY2020 | 78.2× | 0.00% |
| FY2019 | 78.2× | 0.00% |
| FY2018 | 78.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Jun 2022 | −2.0× | — |
| Mar 2022 | −0.3× | — |
| Dec 2021 | −0.2× | — |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| EXOZ eXoZymes Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| ELTX Elicio Therapeutics, Inc. | 0.6× |
| PTHS Pelthos Therapeutics Inc. compare | 1.9× |
| HYPD Hyperion DeFi, Inc. compare | 24.6× |
| GRCE Grace Therapeutics, Inc. compare | 106× |
| IBO Impact Biomedical Inc. compare | 1,228× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)